CoChat

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial

Open access
on behalf of the CONCLUDE Study Group, Philis-Tsimikas, Athena, Klonoff, David C., Khunti, Kamlesh, Bajaj, Harpreet S., Leiter, Lawrence A., Hansen, Melissa V., Troelsen, Lone N., Ladelund, Steen, Heller, Simon, Pieber, Thomas R. · 2020 · Diabetologia

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Aims/hypothesis: A head-to-head randomised trial was conducted to evaluate hypoglycaemia safety with insulin degludec 200 U/ml (degludec U200) and insulin glargine 300 U/ml (glargine U300) in individuals with type 2 diabetes treated with basal insulin. Methods: This randomised (1:1), open-label, treat-to-target, multinational trial included individuals with type 2 diabetes, aged ≥18 years with HbA 1c ≤80 mmol/mol (9.5%) and BMI ≤45 kg/m 2. Participants were previously treated with basal insulin with or without oral glucose-lowering drugs (excluding insulin secretagogues) and had to fulfil at least one predefined criterion for hypoglycaemia risk. Both degludec U200 and glargine U300 were similarly titrated to a fasting blood glucose target of 4.0–5.0 mmol/l. Endpoints were assessed during a 36 week maintenance period and a total treatment period up to 88 weeks. There were three hypoglycaemia endpoints: (1) overall symptomatic hypoglycaemia (either severe, an event requiring third-party assistance, or confirmed by blood glucose [<3.1 mmol/l] with symptoms); (2) nocturnal symptomatic hypoglycaemia (severe or confirmed by blood glucose with symptoms, between 00:01 and 05:59 h); and (3) severe hypoglycaemia. The primary endpoint was the number of overall symptomatic hypoglycaemic events in the maintenance period. Secondary hypoglycaemia endpoints included the number of nocturnal symptomatic events and number of severe hypoglycaemic events during the maintenance period. Results: Of the 1609 randomised participants, 733 of 805 (91.1%) in the degludec U200 arm and 734 of 804 (91.3%) in the glargine U300 arm completed the trial (87.3% and 87.8% completed on treatment, respectively). Baseline characteristics were comparable between the two treatment arms. For the primary endpoint, the rate of overall symptomatic hypoglycaemia was not significantly lower with degludec U200 vs glargine U300 (rate ratio [RR] 0.88 [95% CI 0.73, 1.06]). As there was no significant difference between treatments for the primary endpoint, the confirmatory testing procedure for superiority was stopped. The pre-specified confirmatory secondary hypoglycaemia endpoints were analysed using pre-specified statistical models but were now considered exploratory. These endpoints showed a lower rate of nocturnal symptomatic hypoglycaemia (RR 0.63 [95% CI 0.48, 0.84]) and severe hypoglycaemia (RR 0.20 [95% CI 0.07, 0.57]) with degludec U200 vs glargine U300. Conclusions/interpretation: There was no significant difference in the rate of overall symptomatic hypoglycaemia with degludec U200 vs glargine U300 in the maintenance period. The rates of nocturnal symptomatic and severe hypoglycaemia were nominally significantly lower with degludec U200 during the maintenance period compared with glargine U300. Trial registration: ClinicalTrials.gov NCT03078478 Funding: This trial was funded by Novo Nordisk (Bagsvaerd, Denmark)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-019-05080-9

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Patient disposition. aSome participants fulfilled more than one inclusion or exclusion criterion. bTwo additional participants discontinued treatment before the protocol amendment and neither withdrew nor re-consented. cNew, 36 week maintenance period (52–88 weeks). The number of participants who entered the maintenance period = (participants randomised) – (participants withdrawn from the trial). The number of participants who entered the maintenance period on-treatment = (participants exposed) – (participants who discontinued treatment). The number of participants who completed trial = (participants who entered the maintenance period) – (participants withdrawn from the trial). The number of participants who completed trial on-treatment = (participants who entered the maintenance period on treatment) – (participants who discontinued treatment). Exposed was defined as ‘randomised and received treatment’. The number of participants that discontinued treatment includes the number that withdrew from the trial. FAS, full analysis set; SAS, safety analysis set
Fig. 1 Patient disposition. aSome participants fulfilled more than one inclusion or exclusion criterion. bTwo additional participants discontinued treatment before the protocol amendment and neither withdrew nor re-consented. cNew, 36 week maintenance period (52–88 weeks). The number of participants who entered the maintenance period = (participants randomised) – (participants withdrawn from the trial). The number of participants who entered the maintenance period on-treatment = (participants exposed) – (participants who discontinued treatment). The number of participants who completed trial = (participants who entered the maintenance period) – (participants withdrawn from the trial). The number of participants who completed trial on-treatment = (participants who entered the maintenance period on treatment) – (participants who discontinued treatment). Exposed was defined as ‘randomised and received treatment’. The number of participants that discontinued treatment includes the number that withdrew from the trial. FAS, full analysis set; SAS, safety analysis setCC BY · PubMed Central
Fig. 2 The rate of hypoglycaemia. Overall symptomatic hypoglycaemia was defined as severe hypoglycaemia (an event requiring third-party assistance as per the ADA definition [28]) or blood glucose <3.1 mmol/l confirmed with symptoms. Nocturnal symptomatic hypoglycaemia was defined as severe hypoglycaemia or blood glucose <3.1 mmol/l confirmed with symptoms, occurring between 00:01 and 05:59 h. aPrimary endpoint. E, events; rate, events per 100 person-years of observation
Fig. 2 The rate of hypoglycaemia. Overall symptomatic hypoglycaemia was defined as severe hypoglycaemia (an event requiring third-party assistance as per the ADA definition [28]) or blood glucose <3.1 mmol/l confirmed with symptoms. Nocturnal symptomatic hypoglycaemia was defined as severe hypoglycaemia or blood glucose <3.1 mmol/l confirmed with symptoms, occurring between 00:01 and 05:59 h. aPrimary endpoint. E, events; rate, events per 100 person-years of observationCC BY · PubMed Central
Fig. 3 The proportion of participants with hypoglycaemia (post hoc). Overall symptomatic hypoglycaemia was defined as severe hypoglycaemia (an event requiring third-party assistance as per the ADA definition [28]) or blood glucose <3.1 mmol/l confirmed with symptoms. Nocturnal symptomatic hypoglycaemia was defined as severe hypoglycaemia or blood glucose <3.1 mmol/l confirmed with symptoms, occurring between 00:01 and 05:59 h. %, proportion of participants with events; n, number of participants experiencing events
Fig. 3 The proportion of participants with hypoglycaemia (post hoc). Overall symptomatic hypoglycaemia was defined as severe hypoglycaemia (an event requiring third-party assistance as per the ADA definition [28]) or blood glucose <3.1 mmol/l confirmed with symptoms. Nocturnal symptomatic hypoglycaemia was defined as severe hypoglycaemia or blood glucose <3.1 mmol/l confirmed with symptoms, occurring between 00:01 and 05:59 h. %, proportion of participants with events; n, number of participants experiencing eventsCC BY · PubMed Central
Fig. 4 Hypoglycaemia endpoints during the titration period. Overall symptomatic hypoglycaemia was defined as severe hypoglycaemia (an event requiring third-party assistance as per the ADA definition [28]) or blood glucose <3.1 mmol/l confirmed with symptoms. Nocturnal symptomatic hypoglycaemia was defined as severe hypoglycaemia or blood glucose <3.1 mmol/l confirmed with symptoms, occurring between 00:01 and 05:59 h. %, proportion of participants with events; E, events; n, number of participants with events; rate, events per 100 person-years of observation
Fig. 4 Hypoglycaemia endpoints during the titration period. Overall symptomatic hypoglycaemia was defined as severe hypoglycaemia (an event requiring third-party assistance as per the ADA definition [28]) or blood glucose <3.1 mmol/l confirmed with symptoms. Nocturnal symptomatic hypoglycaemia was defined as severe hypoglycaemia or blood glucose <3.1 mmol/l confirmed with symptoms, occurring between 00:01 and 05:59 h. %, proportion of participants with events; E, events; n, number of participants with events; rate, events per 100 person-years of observationCC BY · PubMed Central
Fig. 5 Hypoglycaemia endpoints during the variable maintenance period. Overall symptomatic hypoglycaemia was defined as severe hypoglycaemia (an event requiring third-party assistance as per the ADA definition [28]) or blood glucose <3.1 mmol/l confirmed with symptoms. Nocturnal symptomatic hypoglycaemia was defined as severe hypoglycaemia or blood glucose <3.1 mmol/l confirmed with symptoms, occurring between 00:01 and 05:59 h. %, proportion of participants with events; E, events; n, number of participants with events; rate, events per 100 person-years of observation
Fig. 5 Hypoglycaemia endpoints during the variable maintenance period. Overall symptomatic hypoglycaemia was defined as severe hypoglycaemia (an event requiring third-party assistance as per the ADA definition [28]) or blood glucose <3.1 mmol/l confirmed with symptoms. Nocturnal symptomatic hypoglycaemia was defined as severe hypoglycaemia or blood glucose <3.1 mmol/l confirmed with symptoms, occurring between 00:01 and 05:59 h. %, proportion of participants with events; E, events; n, number of participants with events; rate, events per 100 person-years of observationCC BY · PubMed Central
Fig. 6 HbA1c, FPG and fasting SMBG over time. (a) HbA1c over the study period. Estimated treatment difference from baseline to end of treatment for degludec U200 vs glargine U300 was −1.07 mmol/mol (95% CI −1.94, −0.20) (−0.10% [95% CI −0.18, −0.02]). (b) FPG over the study period. Estimated treatment difference from baseline to end of treatment for degludec U200 vs glargine U300 was −0.62 mmol/l (95% CI −0.82, −0.43). (c) SMBG over the study period. Estimated treatment difference from baseline to end of treatment for degludec U200 vs glargine U300 was −0.18 mmol/l (95% CI −0.37, 0.01). Data are presented as mean±SEM, with the number of participants (n) shown below each graph. Vertical dotted lines illustrate the end of the titration period (week 16) and the beginning of the maintenance period (week 52). According to the protocol, all participants were not required to complete all visits in the variable maintenance period and therefore the number of participants at each week decreased during this period
Fig. 6 HbA1c, FPG and fasting SMBG over time. (a) HbA1c over the study period. Estimated treatment difference from baseline to end of treatment for degludec U200 vs glargine U300 was −1.07 mmol/mol (95% CI −1.94, −0.20) (−0.10% [95% CI −0.18, −0.02]). (b) FPG over the study period. Estimated treatment difference from baseline to end of treatment for degludec U200 vs glargine U300 was −0.62 mmol/l (95% CI −0.82, −0.43). (c) SMBG over the study period. Estimated treatment difference from baseline to end of treatment for degludec U200 vs glargine U300 was −0.18 mmol/l (95% CI −0.37, 0.01). Data are presented as mean±SEM, with the number of participants (n) shown below each graph. Vertical dotted lines illustrate the end of the titration period (week 16) and the beginning of the maintenance period (week 52). According to the protocol, all participants were not required to complete all visits in the variable maintenance period and therefore the number of participants at each week decreased during this periodCC BY · PubMed Central
Fig. 7 Basal insulin dose over time. Data are presented as mean±SEM, with the number of participants (n) shown below the graph. Vertical dotted lines illustrate the end of the titration period (week 16) and the beginning of the maintenance period (week 52). According to the protocol, all participants were not required to complete all visits in the variable maintenance period and therefore the number of participants at each week decreased during this period
Fig. 7 Basal insulin dose over time. Data are presented as mean±SEM, with the number of participants (n) shown below the graph. Vertical dotted lines illustrate the end of the titration period (week 16) and the beginning of the maintenance period (week 52). According to the protocol, all participants were not required to complete all visits in the variable maintenance period and therefore the number of participants at each week decreased during this periodCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 83

Metadata

Authors
on behalf of the CONCLUDE Study Group, Philis-Tsimikas, A., Klonoff, D. C., Khunti, K., Bajaj, H. S., Leiter, L. A., Hansen, M. V., Troelsen, L. N., Ladelund, S., Heller, S., & Pieber, T. R.
Affiliations
  • Scripps Whittier Diabetes Institute (US)
  • University of Leicester (GB)
  • St. Michael's Hospital (CA)
  • Novo Nordisk (Denmark) (DK)
  • Medical University of Graz (AT)
Venue
Diabetologia
Published
2020-01-27
Volume
63
Issue
4
Pages
698-710
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W3002620086
Cited by
73
References
30
Citations by year
2026: 4 · 2025: 3 · 2024: 8 · 2023: 10 · 2022: 13 · 2021: 17 · 2020: 18
FWCI
10.94
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetologia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
Keywords
insulin degludec, insulin glargine 300 U/mL, type 2 diabetes, hypoglycemia, basal insulin, nocturnal hypoglycemia, severe hypoglycemia, hypoglycemia risk, treatment discontinuation
MeSH terms
Insulin Glargine, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Male, Middle Aged, Risk Factors, Treatment Outcome, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. https://app.cochat.ai/papers/10.1007/s00125-019-05080-9
The paper
on behalf of the CONCLUDE Study Group, Philis-Tsimikas, A., Klonoff, D. C., Khunti, K., Bajaj, H. S., Leiter, L. A., Hansen, M. V., Troelsen, L. N., Ladelund, S., Heller, S., & Pieber, T. R. (2020). Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Diabetologia. https://doi.org/10.1007/s00125-019-05080-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.